Search This Blog

Tuesday, September 24, 2013

Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes (NYSE:LLY)

Data From Post-Hoc Analyses Presented at EASD Examine Safety Profile of Linagliptin in Adults with Type 2 Diabetes (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.